Mar 05, 2012, 10.28 AM IST
Cipla said it had received government notices seeking Rs 425 crore due to over pricing of certain drugs.
The demands are contrary to the orders passed by the Supreme Court of India and are related to the same drugs under litigation, the drugmaker said in a statement.
The company has received a legal advice which says the entire amount demanded by the National Pharmaceutical Pricing Authority (NPPA) is not tenable and sustainable, Cipla said.
NPPA is a government body that fines drugmakers in India if they over price certain drugs that have been identified under the national list of essential medicines.
Cipla stock price
On December 09, 2013, Cipla closed at Rs 385.35, down Rs 3.05, or 0.79 percent. The 52-week high of the share was Rs 450.00 and the 52-week low was Rs 354.40.
The company's trailing 12-month (TTM) EPS was at Rs 18.15 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 21.23. The latest book value of the company is Rs 110.47 per share. At current value, the price-to-book value of the company is 3.49.
Action in Cipla
Video of the day
Dec 6 2013, 15:02
- in MARKET OUTLOOK
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.